Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Calidi announces reverse stock split, expected to begin trading on a 1-for-12 split adjusted basis | 1 | Seeking Alpha | ||
Fr | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Fr | Calidi Biotherapeutics, Inc: Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 | 63 | GlobeNewswire (Europe) | SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted... ► Artikel lesen | |
Di | Calidi Biotherapeutics, Inc: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 | 2 | GlobeNewswire (USA) | ||
10.07. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
10.07. | Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment | 2 | GlobeNewswire (USA) | ||
09.07. | Calidi Biotherapeutics secures $4.6 million through warrant exercise | 4 | Investing.com | ||
CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
09.07. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds | 1 | GlobeNewswire (USA) | ||
08.07. | Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment | 7 | GlobeNewswire (USA) | ||
03.07. | Calidi Biotherapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
27.06. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Shareholder Letter from CEO | 205 | GlobeNewswire (Europe) | SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted... ► Artikel lesen | |
14.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
14.05. | Calidi Biotherapeutics GAAP EPS of -$0.18 misses by $0.03 | 2 | Seeking Alpha | ||
14.05. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
14.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights | 127 | GlobeNewswire (Europe) | Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered... ► Artikel lesen | |
02.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.04. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | 158 | GlobeNewswire (Europe) | SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor... ► Artikel lesen | |
23.04. | Calidi Biotherapeutics appoints new CEO | 2 | Investing.com | ||
23.04. | Calidi Biotherapeutics names Poma as CEO | 4 | Seeking Alpha | ||
23.04. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 98,15 | 0,00 % | BioNTech SE: BioNTech veröffentlicht am 4. August 2025 Ergebnisse für das zweite Quartal 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 21. Juli 2025(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 4. August 2025, die Ergebnisse für das zweite Quartal 2025 veröffentlichen. Darüber hinaus wird... ► Artikel lesen | |
MODERNA | 29,130 | +0,19 % | 3 Charts in 3x33 Sekunden - Heute mit Moderna, Silber und RWE | Willkommen zu '3 Charts in 33 Sekunden'! Jörg Scherer stellt uns drei Charts vor, die er aktuell ganz besonders unter die Lupe nimmt. Welche Ziele oder Signale jetzt wichtig sind, erfahren Sie im Video!... ► Artikel lesen | |
OCUGEN | 0,942 | +0,94 % | Ocugen expands advisory board and leadership team for gene therapy push | ||
VIKING THERAPEUTICS | 29,395 | +0,31 % | Viking Therapeutics nach Zahlen: Geht die Rallye weiter? | Seit meinem letzten Update läuft die Aktie von Viking Therapeutics immer höher. Die Rallye des Biotechs könnte sich nach dem Quartalsbericht von dieser Woche fortsetzen. Sektor erholt sich - Viking... ► Artikel lesen | |
ABCELLERA BIOLOGICS | 4,340 | -0,16 % | Leerink Partners startet Coverage für AbCellera mit "Outperform"-Rating | ||
ALIGOS THERAPEUTICS | 7,750 | 0,00 % | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient... ► Artikel lesen | |
SAGIMET BIOSCIENCES | 8,600 | -1,71 % | Sagimet gains as Canaccord Genuity starts with Buy on potential against MASH | ||
EVOTEC | 7,252 | +6,46 % | Märkte am Morgen: Delivery Hero, Thyssenkrupp, Evotec, Sartorius, Coca-Cola, Block, Nvidia | Der DAX hat zum Auftakt in die neue Handelswoche einen relativ ruhigen Handel erlebt. Zeitweise lag er leicht in der Verlustzone. Letzten Endes schloss er dann aber doch 0,08 Prozent im Plus bei 23.307... ► Artikel lesen | |
QIAGEN | 43,870 | +0,52 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 36,230 | +9,09 % | Avidity Biosciences, Inc.: Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping | -- On track for planned BLA submission for del-zota at year end 2025 --
SAN DIEGO, July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,490 | +3,67 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
ARCELLX | 71,31 | +1,48 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
APOGEE THERAPEUTICS | 40,820 | -1,97 % | Apogee Therapeutics und der 50-Milliarden-Dollar-Markt | Anfang der Woche hatten wir erstmals über Apogee Therapeutics und dessen jüngste Studienergebnisse berichtet. Weiterhin ergibt sich bei der Aktie eine hochattraktive Gelegenheit, die kurzfristige Kursschwäche... ► Artikel lesen | |
COGENT BIOSCIENCES | 12,070 | -0,98 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
IMMUNOVANT | 16,930 | -7,59 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen |